HIV infection and bone disease

• Autores: Juliet Compston
• Localización: Journal of Internal Medicine, ISSN-e 1365-2796, Vol. 280, Nº. 4, 2016, págs. 350-358
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • The success of antiretroviral therapy in treating HIV infection has greatly prolonged life expectancy in affected individuals, transforming the disease into a chronic condition. A number of HIV-associated non-AIDS comorbidities have emerged in the ageing HIV-infected population, including osteoporosis and increased risk of fracture. The pathogenesis of fracture is multifactorial with contributions from both traditional and HIV-specific risk factors. Significant bone loss occurs on initiation of antiretroviral therapy but stabilizes on long-term therapy. Fracture risk assessment should be performed in HIV-infected individuals and bone mineral density measured when indicated. Lifestyle measures to optimize bone health should be advised and, in individuals at high risk of fracture, treatment with bisphosphonates considered.